the definitional overview
What Is Epitalon? A Definitional Overview of the AEDG Tetrapeptide
A tight, citation-anchored answer to the most-asked question about this Russian pineal-bioregulator compound — sequence, origin, mechanism, and the literature's honest limits.
The one-paragraph definition
Epitalon is a synthetic tetrapeptide with the amino-acid sequence Ala-Glu-Asp-Gly (AEDG), developed in the late 1980s and 1990s by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology [1][14]. The molecule was designed from the amino-acid composition of Epithalamin — a crude polypeptide extract of the bovine pineal gland that the Khavinson program had been studying as a putative geroprotector — and represents the defined-sequence synthetic fraction proposed to carry the parent extract's activity [11]. It is studied as a putative telomerase activator, a pineal-axis modulator, and a candidate geroprotector in rodent models [2][6][15].
Sequence and chemistry
The molecule is a linear tetrapeptide of four amino acids — alanine, glutamate, aspartate, glycine — joined by three peptide bonds. Molecular formula C14H22N4O9, molar mass 390.35 g/mol, CAS registry 307297-39-8 for the TFA salt commonly used in research [15]. There are no disulfide bridges, no glycosylation, no other post-translational modifications. The compound's small size and short linear structure make it cheap to synthesise and easy to characterise structurally — but also imply rapid proteolytic clearance in plasma, which has shaped how it is administered in the published studies (parenteral routes dominate; oral bioavailability of the intact peptide is expected to be poor) [15].
Origin: from Epithalamin to AEDG
The Khavinson program began with Epithalamin — a polypeptide extract of bovine pineal gland — in the 1970s and 1980s, reporting effects on melatonin secretion, immune function, and reproductive ageing in rodents and elderly humans [11][12][14]. The synthetic AEDG tetrapeptide was designed to reproduce the parent extract's activity in a defined-sequence form that could be cleanly characterised, dosed, and (in principle) regulated. Where Epithalamin is a complex biological mixture, Epitalon is a single defined molecule — and a substantial portion of the 'Epitalon' clinical claims in the consumer literature are actually claims about Epithalamin that have been extrapolated to its synthetic fraction [11].
What the cellular evidence shows
In cultured human cells, AEDG induces expression of the telomerase catalytic subunit hTERT and elongates telomeres. The seminal demonstration came from Khavinson, Bondarev and Butyugov in Bulletin of Experimental Biology and Medicine in 2003 — fetal fibroblasts, telomerase-negative at baseline, became telomerase-active after exposure to the peptide [1]. The finding was independently replicated by Al-dulaimi and colleagues in Biogerontology in 2025 in normal human fibroblasts (IBR.3) and human mammary epithelial cells (HMEC), with telomere elongation directly measured; in breast cancer lines the same exposure produced little change in telomerase but roughly a ten-fold rise in ALT-pathway activity in 21NT cells [2]. The 2020 Khavinson Molecules paper proposed a histone-binding mechanism, with molecular modelling supporting preferential binding to histones H1/3 and H1/6 at their DNA-interactive sites [3].
What the animal evidence shows
In rodent geroprotection models, monthly subcutaneous courses at microgram-per-mouse doses have produced reproducible effects on tumor frequency and reproductive ageing. In female HER-2/neu transgenic mice, monthly 5-day courses of 1 microgram/mouse reduced cumulative tumor number and maximum mammary-tumor size versus saline controls [4]; tumor size dropped by 33% in a parallel cohort with a 3.7-fold reduction in HER-2/neu mRNA [5]. In Swiss-derived SHR mice, the same monthly protocol slowed reproductive ageing and reduced chromosome-aberration frequency in bone marrow by 17.1%, without changing mean lifespan [6]. In C3H/He mice, six-and-a-half months of 0.1 microgram/mouse five days per week reduced malignant-tumor incidence and prevented metastases without observable toxicity [7].
What the human evidence shows — and where it stops
The human evidence is real but limited. Korkushko and colleagues reported in 2004 that intramuscular Epithalamin courses normalised night-time melatonin secretion in elderly subjects with pineal hypofunction [11], and the 2007 multi-cohort report extended the finding across aged rhesus monkeys and elderly humans [12]. A small parabulbar-injection series in retinitis pigmentosa patients reported improved bioelectric retinal activity in 90% of cases [13]. No large, modern, registered Western randomised controlled trials of the synthetic AEDG tetrapeptide appear on ClinicalTrials.gov as of 2026 [15]. The honest reading: the cellular and rodent evidence is reproducible; the human evidence is real but small, mostly Russian-language, and not yet at the level of modern regulatory drug development.
The literature's geography matters
Most of the positive in vivo and cohort data originate from a single research program — the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. The 2025 Araj review in International Journal of Molecular Sciences makes the point explicitly: twenty-five years of work, a consistent mechanistic and rodent record, but pharmacokinetic characterisation, modern toxicology packages, and large Western human trials remain absent [15]. A reader looking for FDA-grade evidence will not find it. A reader looking for a reproducible cellular signal and a consistent rodent geroprotection signature, with one independent 2025 cell-line replication, will find that.